Genpharmasec Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 7, 2025, 8:23 pm

Market Cap	129 Cr.
Current Price	2.33
High / Low	4.32/1.92
Stock P/E	83.8
Book Value	1.18
Dividend Yield	0.00 %
ROCE	1.52 %
ROE	0.33 %
Face Value	1.00
PEG Ratio	5.79

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Genpharmasec Ltd

Competitors of Genpharmasec Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Mitshi India Ltd	13.4 Cr.	15.2	36.9/14.1		3.06	0.00 %	5.68 %	4.57 %	10.0
Modella Woollens Ltd	5.63 Cr.	61.9	87.0/55.1		2.42	0.00 %	%	%	10.0
MRC Agrotech Ltd	28.4 Cr.	13.8	20.5/10.2		15.2	0.00 %	%	%	10.0
MRP Agro Ltd	149 Cr.	134	174/45.2	30.4	14.6	0.00 %	12.3 %	9.53 %	10.0
Muller and Phipps (India) Ltd	19.7 Cr.	315	726/190		23.8	0.00 %	%	%	10.0
Industry Average	10,440.96 Cr	150.30		103.02	118.54	0.22%	12.66%	9.48%	7.93

All Competitor Stocks of Genpharmasec Ltd

Quarterly Result

Metric	Mar 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	6.22	7.86	6.38	10.20	5.20	6.03	8.48
Expenses	6.01	7.89	6.37	10.21	5.00	5.90	7.74
Operating Profit	0.21	-0.03	0.01	-0.01	0.20	0.13	0.74
OPM %	3.38%	-0.38%	0.16%	-0.10%	3.85%	2.16%	8.73%
Other Income	0.06	0.15	0.14	0.31	0.57	0.75	0.81
Interest	0.06	0.07	0.00	0.16	0.10	0.07	0.16
Depreciation	0.01	0.00	0.12	0.03	0.16	0.30	0.10
Profit before tax	0.20	0.05	0.03	0.11	0.51	0.51	1.29
Tax %	-420.00%	80.00%	-100.00%	345.45%	35.29%	-39.22%	39.53%
Net Profit	1.05	0.01	0.06	-0.27	0.33	0.70	0.78
EPS in Rs	0.02	0.00	0.00	-0.00	0.01	0.01	0.01

Last Updated: March 4, 2025, 12:11 pm

Below is a detailed analysis of the quarterly data for Genpharmasec Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹8.48 Cr.. The value appears strong and on an upward trend. It has increased from 6.03 Cr. (Sep 2024) to ₹8.48 Cr., marking an increase of ₹2.45 Cr..
For Expenses, as of Dec 2024, the value is ₹7.74 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.90 Cr. (Sep 2024) to ₹7.74 Cr., marking an increase of ₹1.84 Cr..
For Operating Profit, as of Dec 2024, the value is ₹0.74 Cr.. The value appears strong and on an upward trend. It has increased from 0.13 Cr. (Sep 2024) to ₹0.74 Cr., marking an increase of ₹0.61 Cr..
For OPM %, as of Dec 2024, the value is 8.73%. The value appears strong and on an upward trend. It has increased from 2.16% (Sep 2024) to 8.73%, marking an increase of 6.57%.
For Other Income, as of Dec 2024, the value is ₹0.81 Cr.. The value appears strong and on an upward trend. It has increased from 0.75 Cr. (Sep 2024) to ₹0.81 Cr., marking an increase of ₹0.06 Cr..
For Interest, as of Dec 2024, the value is ₹0.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Sep 2024) to ₹0.16 Cr., marking an increase of ₹0.09 Cr..
For Depreciation, as of Dec 2024, the value is ₹0.10 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.30 Cr. (Sep 2024) to ₹0.10 Cr., marking a decrease of 0.20 Cr..
For Profit before tax, as of Dec 2024, the value is ₹1.29 Cr.. The value appears strong and on an upward trend. It has increased from 0.51 Cr. (Sep 2024) to ₹1.29 Cr., marking an increase of ₹0.78 Cr..
For Tax %, as of Dec 2024, the value is 39.53%. The value appears to be increasing, which may not be favorable. It has increased from -39.22% (Sep 2024) to 39.53%, marking an increase of 78.75%.
For Net Profit, as of Dec 2024, the value is ₹0.78 Cr.. The value appears strong and on an upward trend. It has increased from 0.70 Cr. (Sep 2024) to ₹0.78 Cr., marking an increase of ₹0.08 Cr..
For EPS in Rs, as of Dec 2024, the value is 0.01. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded ₹0.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 3:54 pm

Metric	Mar 2023	Mar 2024	TTM
Sales	25.52	30.41	29.91
Expenses	25.26	30.37	28.85
Operating Profit	0.26	0.04	1.06
OPM %	1.02%	0.13%	3.54%
Other Income	0.10	0.66	2.44
Interest	0.06	0.41	0.49
Depreciation	0.02	0.04	0.59
Profit before tax	0.28	0.25	2.42
Tax %	-300.00%	168.00%
Net Profit	1.12	-0.17	1.54
EPS in Rs	0.02	-0.00	0.03
Dividend Payout %	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2023-2024
YoY Net Profit Growth (%)	-115.18%
Change in YoY Net Profit Growth (%)	0.00%

Genpharmasec Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 1 years from 2023-2024 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	19%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-112%

Stock Price CAGR
10 Years:	16%
5 Years:	-21%
3 Years:	-15%
1 Year:	-28%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	0%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 3:31 pm

Month	Mar 2023	Mar 2024	Sep 2024
Equity Capital	27.69	55.37	55.37
Reserves	-12.36	9.02	10.03
Borrowings	3.08	3.89	4.89
Other Liabilities	1.46	2.84	5.09
Total Liabilities	19.87	71.12	75.38
Fixed Assets	0.10	0.84	6.30
CWIP	0.00	0.00	0.00
Investments	0.95	19.32	19.40
Other Assets	18.82	50.96	49.68
Total Assets	19.87	71.12	75.38

Below is a detailed analysis of the balance sheet data for Genpharmasec Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹55.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹55.37 Cr..
For Reserves, as of Sep 2024, the value is ₹10.03 Cr.. The value appears strong and on an upward trend. It has increased from ₹9.02 Cr. (Mar 2024) to ₹10.03 Cr., marking an increase of 1.01 Cr..
For Borrowings, as of Sep 2024, the value is ₹4.89 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹3.89 Cr. (Mar 2024) to ₹4.89 Cr., marking an increase of 1.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹5.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹2.84 Cr. (Mar 2024) to ₹5.09 Cr., marking an increase of 2.25 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹75.38 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹71.12 Cr. (Mar 2024) to ₹75.38 Cr., marking an increase of 4.26 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹6.30 Cr.. The value appears strong and on an upward trend. It has increased from ₹0.84 Cr. (Mar 2024) to ₹6.30 Cr., marking an increase of 5.46 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹19.40 Cr.. The value appears strong and on an upward trend. It has increased from ₹19.32 Cr. (Mar 2024) to ₹19.40 Cr., marking an increase of 0.08 Cr..
For Other Assets, as of Sep 2024, the value is ₹49.68 Cr.. The value appears to be declining and may need further review. It has decreased from ₹50.96 Cr. (Mar 2024) to ₹49.68 Cr., marking a decrease of 1.28 Cr..
For Total Assets, as of Sep 2024, the value is ₹75.38 Cr.. The value appears strong and on an upward trend. It has increased from ₹71.12 Cr. (Mar 2024) to ₹75.38 Cr., marking an increase of 4.26 Cr..

Notably, the Reserves (₹10.03 Cr.) exceed the Borrowings (4.89 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2023	Mar 2024
Cash from Operating Activity +	-3.06	-2.95
Cash from Investing Activity +	0.36	-28.06
Cash from Financing Activity +	3.08	47.85
Net Cash Flow	0.39	16.84

Free Cash Flow

Month	Mar 2023	Mar 2024
Free Cash Flow	-2.82	-3.85

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2023	Mar 2024
Debtor Days	81.67	109.22
Inventory Days	151.06	133.17
Days Payable	21.38	35.85
Cash Conversion Cycle	211.34	206.54
Working Capital Days	207.67	213.17
ROCE %		1.52%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	59.96%	59.96%	59.96%	59.96%	59.96%	59.96%	59.96%	59.96%	29.98%	29.98%	29.98%	29.98%
Public	40.04%	40.04%	40.03%	40.04%	40.03%	40.03%	40.04%	40.04%	70.02%	70.02%	70.02%	70.02%
No. of Shareholders	54,007	53,404	53,266	51,435	49,760	48,868	54,458	89,438	1,08,137	1,08,220	1,05,838	1,09,206

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24
FaceValue	1.00
Basic EPS (Rs.)	-0.01
Diluted EPS (Rs.)	-0.01
Book Value[Excl.RevalReserv]/Share (Rs.)	1.17
Book Value[Incl.RevalReserv]/Share (Rs.)	1.17
Revenue From Operations / Share (Rs.)	0.54
PBDIT / Share (Rs.)	0.01
PBIT / Share (Rs.)	0.01
PBDIT Margin (%)	2.30
PBIT Margin (%)	2.16
PBT Margin (%)	0.82
Net Profit Margin (%)	-0.55
NP After MI And SOA Margin (%)	-0.41
Return on Networth / Equity (%)	-0.19
Return on Capital Employeed (%)	0.96
Return On Assets (%)	-0.17
Long Term Debt / Equity (X)	0.04
Total Debt / Equity (X)	0.04
Current Ratio (X)	15.16
Quick Ratio (X)	11.89
Interest Coverage Ratio (X)	1.72
Interest Coverage Ratio (Post Tax) (X)	0.58
Enterprise Value (Cr.)	108.00
EV / Net Operating Revenue (X)	3.55
EV / EBITDA (X)	153.89
MarketCap / Net Operating Revenue (X)	4.06
Price / BV (X)	1.92
Price / Net Operating Revenue (X)	4.06

After reviewing the key financial ratios for Genpharmasec Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. No previous period data is available for comparison.
For Basic EPS (Rs.), as of Mar 24, the value is -0.01. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Diluted EPS (Rs.), as of Mar 24, the value is -0.01. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 1.17. No previous period data is available for comparison.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 1.17. No previous period data is available for comparison.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 0.54. No previous period data is available for comparison.
For PBDIT / Share (Rs.), as of Mar 24, the value is 0.01. This value is below the healthy minimum of 2. No previous period data is available for comparison.
For PBIT / Share (Rs.), as of Mar 24, the value is 0.01. This value is within the healthy range. No previous period data is available for comparison.
For PBDIT Margin (%), as of Mar 24, the value is 2.30. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For PBIT Margin (%), as of Mar 24, the value is 2.16. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For PBT Margin (%), as of Mar 24, the value is 0.82. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Net Profit Margin (%), as of Mar 24, the value is -0.55. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For NP After MI And SOA Margin (%), as of Mar 24, the value is -0.41. This value is below the healthy minimum of 8. No previous period data is available for comparison.
For Return on Networth / Equity (%), as of Mar 24, the value is -0.19. This value is below the healthy minimum of 15. No previous period data is available for comparison.
For Return on Capital Employeed (%), as of Mar 24, the value is 0.96. This value is below the healthy minimum of 10. No previous period data is available for comparison.
For Return On Assets (%), as of Mar 24, the value is -0.17. This value is below the healthy minimum of 5. No previous period data is available for comparison.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.04. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
For Total Debt / Equity (X), as of Mar 24, the value is 0.04. This value is within the healthy range. No previous period data is available for comparison.
For Current Ratio (X), as of Mar 24, the value is 15.16. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
For Quick Ratio (X), as of Mar 24, the value is 11.89. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
For Interest Coverage Ratio (X), as of Mar 24, the value is 1.72. This value is below the healthy minimum of 3. No previous period data is available for comparison.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.58. This value is below the healthy minimum of 3. No previous period data is available for comparison.
For Enterprise Value (Cr.), as of Mar 24, the value is 108.00. No previous period data is available for comparison.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.55. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
For EV / EBITDA (X), as of Mar 24, the value is 153.89. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.06. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
For Price / BV (X), as of Mar 24, the value is 1.92. This value is within the healthy range. No previous period data is available for comparison.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.06. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Genpharmasec Ltd as of March 10, 2025 is: ₹0.27

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 10, 2025, Genpharmasec Ltd is Overvalued by 88.41% compared to the current share price 2.33

Intrinsic Value of Genpharmasec Ltd as of March 10, 2025 is: 0.31

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 10, 2025, Genpharmasec Ltd is Overvalued by 86.70% compared to the current share price 2.33

Last 5 Year EPS CAGR: 14.47%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has shown consistent growth in sales (28.61 cr) and profit (0.98 cr) over the years.	The stock has a low average ROCE of 0.76%, which may not be favorable. The stock has a high average Working Capital Days of 210.42, which may not be favorable. The stock has a high average Cash Conversion Cycle of 208.94, which may not be favorable. The company has higher borrowings (3.95) compared to reserves (2.23), which may suggest financial risk.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genpharmasec Ltd:
1. Net Profit Margin: -0.55%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 0.96% (Industry Average ROCE: 11.64%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: -0.19% (Industry Average ROE: 8.09%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 0.58
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 11.89
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 83.8 (Industry average Stock P/E: 70.05)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.04
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Genpharmasec Ltd. is a Public Limited Listed company incorporated on 16/11/1992 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24231MH1992PLC323914 and registration number is 018572. Currently company belongs to the Industry of Trading & Distributors. Company's Total Operating Revenue is Rs. 30.41 Cr. and Equity Capital is Rs. 55.37 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Trading & Distributors	Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises Co-Operative Society Ltd., Mumbai Maharashtra 400101	compliance@genpharmasec.com http://www.genpharmasec.com

Management
Name	Position Held
Mr. Sohan Chaturvedi	WholeTime Director & CFO
Mrs. Sneha Sadhwani	Non Exe.Non Ind.Director
Mr. Rajesh Mirchumal Sadhwani	Non Exe.Non Ind.Director
Mr. Siddhesh Shende	Independent Director
Mr. Mayur Bhatt	Independent Director
Mr. Sachin Prakash Aphandkar	Independent Director

FAQ

What is the latest intrinsic value of Genpharmasec Ltd?

The latest intrinsic value of Genpharmasec Ltd as on 10 March 2025 is ₹0.27, which is 88.41% lower than the current market price of 2.33, indicating the stock is overvalued by 88.41%. The intrinsic value of Genpharmasec Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹129 Cr. and recorded a high/low of ₹4.32/1.92 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹10.03 Cr and total liabilities of ₹75.38 Cr.

What is the Market Cap of Genpharmasec Ltd?

The Market Cap of Genpharmasec Ltd is 129 Cr..

What is the current Stock Price of Genpharmasec Ltd as on 10 March 2025?

The current stock price of Genpharmasec Ltd as on 10 March 2025 is ₹2.33.

What is the High / Low of Genpharmasec Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Genpharmasec Ltd stocks is ₹4.32/1.92.

What is the Stock P/E of Genpharmasec Ltd?

The Stock P/E of Genpharmasec Ltd is 83.8.

What is the Book Value of Genpharmasec Ltd?

The Book Value of Genpharmasec Ltd is 1.18.

What is the Dividend Yield of Genpharmasec Ltd?

The Dividend Yield of Genpharmasec Ltd is 0.00 %.

What is the ROCE of Genpharmasec Ltd?

The ROCE of Genpharmasec Ltd is 1.52 %.

What is the ROE of Genpharmasec Ltd?

The ROE of Genpharmasec Ltd is 0.33 %.

What is the Face Value of Genpharmasec Ltd?

The Face Value of Genpharmasec Ltd is 1.00.